Aldeyra Therapeutics (ALDX) Competitors $4.88 +0.02 (+0.41%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ALDX vs. CALT, SPRY, ANIP, SNDX, INVA, ELVN, RCKT, BCYC, OPK, and AVDLShould you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), ANI Pharmaceuticals (ANIP), Syndax Pharmaceuticals (SNDX), Innoviva (INVA), Enliven Therapeutics (ELVN), Rocket Pharmaceuticals (RCKT), Bicycle Therapeutics (BCYC), OPKO Health (OPK), and Avadel Pharmaceuticals (AVDL). These companies are all part of the "pharmaceutical preparations" industry. Aldeyra Therapeutics vs. Calliditas Therapeutics AB (publ) ARS Pharmaceuticals ANI Pharmaceuticals Syndax Pharmaceuticals Innoviva Enliven Therapeutics Rocket Pharmaceuticals Bicycle Therapeutics OPKO Health Avadel Pharmaceuticals Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability, risk and community ranking. Which has more risk and volatility, CALT or ALDX? Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Does the MarketBeat Community favor CALT or ALDX? Aldeyra Therapeutics received 455 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 69.35% of users gave Aldeyra Therapeutics an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% Aldeyra TherapeuticsOutperform Votes48269.35% Underperform Votes21330.65% Is CALT or ALDX more profitable? Aldeyra Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Aldeyra Therapeutics' return on equity of -43.01% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Aldeyra Therapeutics N/A -43.01%-33.62% Do analysts prefer CALT or ALDX? Calliditas Therapeutics AB (publ) presently has a consensus price target of $39.25, indicating a potential downside of 1.88%. Aldeyra Therapeutics has a consensus price target of $10.00, indicating a potential upside of 104.92%. Given Aldeyra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Aldeyra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CALT or ALDX? In the previous week, Aldeyra Therapeutics had 2 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Aldeyra Therapeutics' average media sentiment score of 1.80 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Aldeyra Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Aldeyra Therapeutics Very Positive Which has stronger earnings & valuation, CALT or ALDX? Aldeyra Therapeutics has lower revenue, but higher earnings than Calliditas Therapeutics AB (publ). CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Aldeyra TherapeuticsN/AN/A-$37.54MN/AN/A Do insiders and institutionals believe in CALT or ALDX? 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryAldeyra Therapeutics beats Calliditas Therapeutics AB (publ) on 12 of the 15 factors compared between the two stocks. Ad Brownstone ResearchMedia Humiliated: Demo of Elon’s Tech Proves They’re WrongElon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it.Click here to watch this demo and decide for yourself. Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALDX vs. The Competition Export to ExcelMetricAldeyra TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$290.60M$6.57B$5.14B$9.08BDividend YieldN/A2.98%5.09%4.23%P/E RatioN/A10.5089.8217.18Price / SalesN/A195.801,116.21116.95Price / CashN/A57.1642.8937.86Price / Book2.395.094.784.78Net Income-$37.54M$151.83M$120.23M$225.60M7 Day Performance-0.41%-2.13%-1.92%-1.23%1 Month Performance1.46%-3.10%11.49%3.36%1 Year Performance45.67%11.54%30.57%16.60% Aldeyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALDXAldeyra Therapeutics2.4313 of 5 stars$4.88+0.4%$10.00+104.9%+45.2%$290.60MN/A0.0015Positive NewsCALTCalliditas Therapeutics AB (publ)0.065 of 5 stars$40.00-0.4%$39.25-1.9%N/A$1.19B$1.60B-21.62180SPRYARS Pharmaceuticals3.1441 of 5 stars$12.26+3.0%$24.00+95.8%+121.8%$1.19B$30,000.00-23.3390Insider TradeNews CoverageANIPANI Pharmaceuticals4.836 of 5 stars$56.07-0.9%$77.71+38.6%+1.9%$1.18B$555.46M-102.89642Insider TradeSNDXSyndax Pharmaceuticals3.952 of 5 stars$13.73-1.4%$37.64+174.1%-33.6%$1.17B$16M-3.84110News CoverageINVAInnoviva1.9799 of 5 stars$18.54-0.2%N/A+11.7%$1.16B$310.46M26.93112ELVNEnliven Therapeutics2.7848 of 5 stars$23.55+1.7%$38.25+62.4%+84.3%$1.15BN/A-12.4350RCKTRocket Pharmaceuticals4.8494 of 5 stars$11.94-0.7%$51.00+327.1%-58.6%$1.09BN/A-4.37240Analyst ForecastBCYCBicycle Therapeutics3.6084 of 5 stars$15.46+11.9%$36.00+132.9%-18.8%$1.07B$26.98M-4.56240Analyst ForecastInsider TradeAnalyst RevisionNews CoverageHigh Trading VolumeOPKOPKO Health4.1754 of 5 stars$1.55-2.8%$2.75+78.0%-1.3%$1.05B$711.41M-8.343,930Analyst UpgradePositive NewsAVDLAvadel Pharmaceuticals2.6635 of 5 stars$10.93+5.2%$24.43+123.5%-24.0%$1.05B$138.16M-13.15154Positive News Related Companies and Tools Related Companies CALT Competitors SPRY Competitors ANIP Competitors SNDX Competitors INVA Competitors ELVN Competitors RCKT Competitors BCYC Competitors OPK Competitors AVDL Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALDX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALDX Stock Alerts